After its cannabidiol gel candidate failed a phase 3 trial in fragile X syndrome, Harmony Biosciences has now paused development of the asset in a different genetic disease. Harmony announced in ...
The cover artistically integrates multiple elements central to investigating the developmental origins of Fragile X syndrome. A vibrant DNA double helix structure rendered in rainbow iridescent colors ...
A new study shows that enhancing activity of a specific component of 'NMDA' receptors normalizes protein synthesis, neural activity and seizure susceptibility in the hippocampus of fragile X lab mice.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback